10x Genomics (TXG) Share-based Compensation (2018 - 2026)

10x Genomics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $22.6 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 27.14% year-over-year to $22.6 million; the TTM figure through Mar 2026 stood at $100.7 million (down 25.8% YoY), while the FY2025 annual figure was $109.1 million, down 22.47% from the prior year.
• Share-based Compensation came in at $22.6 million for Q1 2026 at 10x Genomics, down from $25.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $45.7 million in Q2 2023 to a low of $22.6 million in Q1 2026.
• A 5-year average of $33.9 million and a median of $33.6 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation soared 61.63% in 2023 and slipped 28.4% in 2025, its largest moves.
• 10x Genomics' Share-based Compensation stood at $41.0 million in 2022, then fell by 5.02% to $38.9 million in 2023, then fell by 16.39% to $32.5 million in 2024, then dropped by 22.5% to $25.2 million in 2025, then fell by 10.22% to $22.6 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $22.6 million, $25.2 million, and $25.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison